Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Breast Neoplasms 10Ovarian Neoplasms 9Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 5Neoplasms 4Astrocytoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Glioblastoma 3Uterine Cervical Neoplasms 2Thrombocythemia, Essential 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Medulloblastoma 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hereditary Breast and Ovarian Cancer Syndrome 2Gliosarcoma 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms, Male 2Brain Neoplasms 2

Interventions

fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Cyclophosphamide 4Carboplatin 4Topotecan 3Filgrastim 3Etoposide 3Cytarabine 3veliparib 2tipifarnib 2Prednisone 2Imatinib Mesylate 2Decitabine 2Cyclosporine 2Busulfan 2tanespimycin 1sargramostim 1romidepsin 1iadademstat 1decitabine and cedazuridine drug combination 1Vorinostat 1Vitamin E 1Vincristine 1Thiotepa 1Tacrolimus 1Sunitinib 1Specimen Handling 1Rituximab 1Radiotherapy 1Pharmacogenomic Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Polycythemia Vera × veliparib × Clear all
NCT03289910 2026-04-13

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
25 enrolled 15 charts
MyeloidOther hematologic neoplasm

Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00588991 2025-04-02

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡